HMGB1 and glioblastoma: Augmented release of HMGB1 by tumor cells on cytotoxic treatment with Ad-TK (+ganciclovir) was even detected to be part of activating effective immune response against glioblastoma cells—a noteworthy fact, as usually the blood-brain barrier prevents immune response [146].